Exonhit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease
PARIS, France, March 15 -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announces that it has reached an important milestone in the differentiation, from blood, of patients with Alzheimer's disease from patients with no cognitive impairments.
Scientific data, which are presented at the 8th International Conference on Alzheimer and Parkinson diseases in Salzburg, Austria, are expected to lead to the development of novel diagnostic tests that will enable the detection of Alzheimer's disease from blood. Such tests should also facilitate recruitment of patients for the evaluation of therapeutic entities in the context of clinical trials.
The scientific data shows that a panel of 60 biomarkers can clearly distinguish individuals, males or females, presenting the symptoms of Alzheimer's disease as judged by a MMSE (Mini Mental State Examination) score